|
refractory multiple myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Daratumumab (DARA) is a humanized Immunoglobulin G(IgG)1-kappa monoclonal antibody against CD38 antigen that is shown to improve outcomes in relapsed/refractory plasma cell myeloma (PCM) patients.
|
31313879 |
2020 |
|
refractory multiple myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The anti-CD38 antibody daratumumab is approved for treatment of refractory multiple myeloma and acts by depletion of plasma cells and modification of various T-cell functions.
|
31630242 |
2020 |
|
refractory multiple myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Pretreatment CD38-positive regulatory T-cells affect the durable response to daratumumab in relapsed/refractory multiple myeloma patients.
|
31004032 |
2020 |
|
refractory multiple myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy.
|
30858549 |
2019 |
|
refractory multiple myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The fist in class CD38-targeting antibody, daratumumab, is currently approved as single agent and in combination with standards of care for the treatment of relapsed and refractory multiple myeloma.
|
30826127 |
2019 |
|
refractory multiple myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Daratumumab is a human immunoglobulin G1κ monoclonal antibody that binds CD38, and has been demonstrated to be safe and effective in patients with refractory multiple myeloma.
|
29305553 |
2018 |
|
refractory multiple myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The fist in class CD38-targeting antibody, daratumumab, is currently approved as single agent and in combination with standards of care for the treatment of relapsed and refractory multiple myeloma.
|
29702148 |
2018 |
|
refractory multiple myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The approval of the first two monoclonal antibodies targeting CD38 (daratumumab) and SLAMF7 (elotuzumab) in late 2015 for treating relapsed and refractory multiple myeloma (RRMM) was a critical advance for immunotherapies for multiple myeloma (MM).
|
30147690 |
2018 |
|
refractory multiple myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In recent years, the anti-CD38 monoclonal antibody daratumumab (Darzalex; Janssen-Cilag Pty Ltd) has been shown to be highly efficacious in relapsed and refractory multiple myeloma, with the final results of treatment in newly diagnosed patients awaited.
|
29415351 |
2018 |
|
refractory multiple myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
There is an increasing demand for daratumumab (DARA), an immunoglobulin (Ig)G1κ monoclonal antibody (MoAb) that recognizes CD38, to manage relapsed or refractory multiple myeloma (MM) patients.
|
30267414 |
2018 |
|
refractory multiple myeloma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Daratumumab, a CD38 human monoclonal antibody, demonstrated significant clinical activity in combination with bortezomib and dexamethasone <i>versus</i> bortezomib and dexamethasone alone in the primary analysis of CASTOR, a phase 3 study in relapsed and/or refractory multiple myeloma.
|
30237264 |
2018 |
|
refractory multiple myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Daratumumab is a human CD38-directed monoclonal antibody indicated for the treatment of relapsed and refractory multiple myeloma (MM).
|
30395359 |
2018 |
|
refractory multiple myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Background Daratumumab (Darzalex) is a human IgG1 kappa monoclonal antibody targeting CD38 that has been recently approved for the treatment of refractory multiple myeloma.
|
28490184 |
2018 |
|
refractory multiple myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Intravenous daratumumab (DARZALEX<sup>®</sup>) is a first-in-class human IgG1κ monoclonal antibody against CD38 available for use in patients with relapsed and/or refractory multiple myeloma.
|
29127588 |
2017 |
|
refractory multiple myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Anti-CD38 is used to treat relapsed or treatment-refractory multiple myeloma.
|
28474469 |
2017 |
|
refractory multiple myeloma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Daratumumab, a human CD38 imunoglobulin G 1κ monoclonal antibody, has demonstrated clinical activity and a manageable safety profile in monotherapy and combination therapy clinical trials in relapsed and/or refractory multiple myeloma.
|
29296857 |
2017 |